NCT00848562

Completed

Nicorandil Study to Reduce Cardiac Death After Percutaneous ...

Toujinkai Hospital Source

Compare

Other study identifiers

Sponsor study identifier

NICO-HDPCI-1

Study Type

interventional

Actual enrollment (reported)

129

Locations

1 country

Sites

1

Timeline

Study Start

January 2002

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2006

Actual (reported)

Study Completion

December 2006

Actual (reported)

Brief Summary

Survival after invasive coronary revascularization is worse in patients with chronic kidney disease than in those without it. The investigators aimed to examine whether oral administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener, could improve the survival of end-stage renal disease patients with coronary artery disease by inhibiting cardiac death after coronary revascularization.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 129 participants
Study completion date: December 2006
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2002
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
December 2006
Actual (reported)
Study Completion
December 2006
Actual (reported)
First Submitted
February 19, 2009
Actual (reported)
First Posted
February 20, 2009
Actual (reported)

Last Updated: February 20, 2009
Status Verified: February 2009
Last Update Submitted: February 19, 2009

Conditions

Acute Myocardial Infarction Congestive Heart Failure

Keywords

sudden cardiac death

Outcome Measures

Primary Outcomes (1)

Cardiac death (sudden cardiac death, deaths due to acute myocardial infarction or congestive heart failure)
Jan 1, 2002 to Dec 31, 2006

Secondary Outcomes (1)

All-cause mortality
Jan 1, 2002 to Dec 31, 2006

Study Arms (1)

Nicorandil

EXPERIMENTAL

Drug: Nicorandil

Interventions

NicorandilDrug

Oral administration of nicorandil (15 mg/day)

Nicorandil

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age30 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Hemodialysis patients with coronary artery disease who had undergone a successful first PCI with bare-metal stents between July 1, 2001 and December 31, 2003.

You may not qualify if:

Sponsors & Collaborators

Toujinkai Hospital
Otherlead

Study Sites (1)

Toujinkai Hospital

Kyoto, Kyoto, 612-8026, Japan

MeSH Terms

Conditions

Heart FailureDeath, Sudden, Cardiac

Interventions

Nicorandil

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesHeart ArrestDeath, SuddenDeathPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

NitratesOrganic ChemicalsNiacinamide

Enrollment

129 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: PREVENTION
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER

Study Record Dates

First Submitted

February 19, 2009

First Posted

February 20, 2009

Study Start

January 2002

Date type not reported

This date has not been verified as actual or estimated.

NCT01475123

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Phase 4Active Not Recruiting

NCT00105703

Evaluation of a Nurse Case Management Model for Chronic Heart Failure

Not ApplicableCompleted

NCT01401036

Nobori And Uncoated Stent In Coronary Attack

Not ApplicableTerminated

NCT00389649

Effect of Chronic Changes in Heart Rate on Congestive Heart Failure

Not ApplicableCompleted

NCT00309764

CHF Management Using Telemedicine

Not ApplicableCompleted

NCT01226563

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

Not ApplicableCompleted

Subjects with moderate or worse cardiac valvular disease or old myocardial infarction at the point of first PCI.

Contact the study team to confirm eligibility.

Nicotinic Acids

Acids, Heterocyclic

Heterocyclic Compounds

Pyridines

Heterocyclic Compounds, 1-Ring

Primary Completion

December 2006

Actual (reported)

Study Completion

December 2006

Actual (reported)

Last Updated

February 20, 2009

Record last verified: 2009-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00848562
Data provider: ClinicalTrials.gov
Source updated: 2009-02-20
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:24:52 UTC

Locations

JP(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Nicorandil

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

Source record

Locations